Skip to search formSkip to main contentSkip to account menu

SR26334

National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Ticlopidine
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Acetylsalicylic Acid in Fixed-Dose Combination with Clopidogrel Versus Enteric Aspirin in Chinese Subjects…
Introduction Dual antiplatelet therapy, aspirin and a P2Y 12 inhibitor, is recommended to prevent thrombotic complications of… 
2015
2015
Influence of CYP2C19 loss‐of‐function variants on the metabolism of clopidogrel in patients from north‐western China
Variation of the cytochrome P450 2C19 gene coding for the CYP2C19 enzyme has been reported to be associated with clopidogrel… 
2013
2013
Determination of SR26334 in rats plasma by LC-MS/MS and study of its pharmacokinetics
OBJECTIVE To develop a LC-MS /MS method for the determination of Clopidogrel carboxylic acid metabolites SR26334 in rat plasma… 
2012
2012
Comparative Pharmacokinetics/Pharmacodynamics of Clopidogrel Besylate and Clopidogrel Bisulfate in Healthy Korean Subjects
BackgroundClopidogrel selectively inhibits platelet aggregation. Clopidogrel bisulfate (Plavix®) was first developed for… 
2012
2012
[Impact of clopidogrel carboxylic metabolite SR26334 on gene expression profile of human umbilical vein endothelial cell line].
This study was purposed to characterize the effect of carboxylic acid metabolite (SR26334) of clopidogrel bisulfate deprived of… 
2010
2010
Pharmacokinetics and the antiplatelet effect of a new clopidogrel formulation, clopidogrel besylate, in healthy subjects.
BACKGROUND Clopidogrel, a thienopyridine derivative, is an inhibitor of platelet aggregation induced by adenosine diphosphate… 
2008
2008
Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects
ObjectiveClopidogrel is activated by cytochrome P450 3A (CYP3A) to generate an active metabolite that inhibits adenosine… 
1999
1999
Clopidogrel bioavailability: absence of influence of food or antacids.
Two open, randomized, crossover bioavailability studies were carried out to assess the influence of concurrent antacid medication… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)